Infinity forms alliance with Johnson & Johnson
Cancer drug discovery company Infinity Pharmaceuticals has entered into a collaborative agreement enabling Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica, to identify novel, small molecule therapeutic agents using Infinity's novel compound collection.
Cancer drug discovery company Infinity Pharmaceuticals has entered into a collaborative agreement enabling Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica, to identify novel, small molecule therapeutic agents using Infinity's novel compound collection.
Infinity will provide J&JPRD with non-exclusive access to a proprietary collection of small molecules, which J&JPRD may screen broadly against multiple targets and use to identify small molecule drug leads.
The industrialised nature of the Infinity platform enables it to be scaled for widespread use within J&JPRD, thereby capitalising on the platform's potential for broad therapeutic utility across numerous disease areas.
Additionally, Johnson & Johnson Development Corporation, an affiliate of J&JPRD, has made an equity investment in Infinity. Other financial details were not disclosed.